Study guide
14.3 Temporary & Permanent Contraceptive Methods in India
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
14.3 Temporary & Permanent Contraceptive Methods in India
Key Takeaways Explain This Topic AI
India's National Family Welfare Programme provides a comprehensive basket of contraceptive choices, including Mala-N/Mala-D (COCPs), Chhaya (Centchroman), Antara (DMPA injectable), Cu-T 380A/375, and LNG-IUS.
Pearl Index quantifies contraceptive failure rates per 100 woman-years of exposure; subdermal implants (0.05), LNG-IUS (0.2), and vasectomy (0.15) represent the most effective methods.
Centchroman (Ormeloxifene / Chhaya) is a unique Indian non-steroidal selective estrogen receptor modulator (SERM) administered twice weekly for 12 weeks followed by once weekly, preventing implantation without suppressing ovulation.
Cu-T 380A provides 10 years of continuous protection by eliciting a localized sterile inflammatory reaction toxic to spermatozoa; it can be inserted as an interval method or within 48 hours post-partum (PPIUCD).
No-Scalpel Vasectomy (NSV) requires mandatory condom backup for 3 months or 20 ejaculations until Post-Vasectomy Semen Analysis (PVSA) confirms complete azoospermia.
Last updated: July 2026
14.3 Temporary & Permanent Contraceptive Methods in India
Family Planning is a key component of national health policy in India. India was the first country in the world to initiate a National Family Planning Programme in 1952. Under the modern Reproductive, Maternal, Newborn, Child and Adolescent Health (RMNCH+A) strategy and Mission Parivar Vikas , the government has expanded the 'Basket of Choice' to ensure universal access to high-quality spacing and permanent contraceptive modalities.
Quantifying Efficacy: The Pearl Index
Contraceptive efficacy is evaluated objectively using the Pearl Index , defined as the number of unintended pregnancies per 100 woman-years of exposure (equivalent to 1,200 months of use): Pearl Index = Total Unintended Pregnancies × 1200 Total Months of Exposure (or Woman-Months) \text{Pearl Index} = \frac{\text{Total Unintended Pregnancies} \times 1200}{\text{Total Months of Exposure (or Woman-Months)}} Pearl Index = Total Months of Exposure (or Woman-Months) Total Unintended Pregnancies × 1200
A lower Pearl Index indicates higher contraceptive efficacy. Clinical guidelines distinguish between Perfect Use (failure rate under ideal, error-free trial conditions) and Typical Use (failure rate reflecting real-world inconsistent or incorrect use).
- Temporary (Spacing) Contraceptive Methods
- 1. Combined Oral Contraceptive Pills (COCPs - Mala-N & Mala-D)
Composition: 21 active hormonal tablets containing Levonorgestrel 0.15 mg (150 mcg) + Ethinylestradiol 0.03 mg (30 mcg) , followed by 7 brown iron tablets (Ferrous Fumarate 60 mg) to maintain daily pill-taking habits and treat anemia.
Mala-N: Distributed free of charge in government health facilities.
Mala-D: Socially marketed at a subsidized price.
Mechanism of Action: Ethinylestradiol suppresses pituitary FSH secretion (inhibiting follicular development), while progestin suppresses the LH surge (preventing ovulation), thickens cervical mucus (impeding sperm transport), and alters the endometrium.
WHO Medical Eligibility Criteria (Category 4 - Absolute Contraindications):
Age >35 years and heavy smoker (≥15 cigarettes/day).
History of or current Venous Thromboembolism (DVT / Pulmonary Embolism).
Ischemic heart disease, stroke, or complicated valvular heart disease.
Severe hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg).
Breast cancer (current or within past 5 years).
Migraine with focal neurological aura at any age.
Acute hepatitis, severe cirrhosis, or liver tumors.
2. Centchroman / Ormeloxifene (Chhaya / Saheli)
Unique Indian Innovation: Developed by the Central Drug Research Institute (CDRI), Lucknow. It is a non-steroidal, non-hormonal Selective Estrogen Receptor Modulator (SERM) .
Mechanism of Action: Acts as an estrogen antagonist in the endometrium (rendering it unreceptive to blastocyst implantation) and accelerates tubal transport of ova. Crucially, it does not suppress ovulation or disrupt the hypothalamic-pituitary-ovarian axis.
Dosing Schedule: 30 mg tablet taken twice weekly for the first 12 weeks (e.g., Sunday and Wednesday), followed by 30 mg once weekly thereafter (on the first day taken).
Side Effect Profile: Highly safe with no risk of thromboembolism, weight gain, or hormonal neoplasia. The primary side effect is a benign delay in menses in ~8% of cycles.
3. Injectable Progestin Contraceptives (Antara Program)
DMPA (Depot Medroxyprogesterone Acetate): 150 mg IM deep gluteal/deltoid injection every 3 months (12 weeks).
NET-EN (Norethisterone Enanthate): 200 mg IM injection every 2 months (8 weeks).
Mechanism: Sustained progestin levels inhibit LH surge (preventing ovulation) and thicken cervical mucus.
Clinical Considerations: High incidence of menstrual irregularities (irregular spotting initially, progressing to complete amenorrhea in >50% of users by 1 year). Prolonged use (>2 years) causes reversible loss of bone mineral density (BMD). Return of fertility may be delayed by 6 to 10 months post-discontinuation.
4. Intrauterine Contraceptive Devices (IUCDs)
Copper IUCDs (Cu-T 380A & Cu-T 375):
Cu-T 380A: Active duration of 10 years . Features 380 mm² of surface copper wire wrapped around the stem and solid copper sleeves on the horizontal arms.
Cu-T 375: Active duration of 5 years .
Mechanism: Copper ions induce a localized, sterile, foreign-body inflammatory response within the endometrium, producing cytotoxic effects on spermatozoa and preventing fertilization.
Timing of Insertion: Interval (within 7 days of menses onset), Postpartum (PPIUCD within 10 minutes of placental delivery or up to 48 hours postpartum), or Post-abortal.
Complications: Menorrhagia and dysmenorrhea (most common reason for removal), uterine perforation (~1 in 1,000, highest in lactating women), and expulsion (~5-10%).
Hormone-Releasing IUCD (LNG-IUS / Mirena / Chhaya-IUS):
Releases 20 mcg levonorgestrel daily into the uterine cavity; active for 5 to 8 years .
Induces profound localized endometrial atrophy; primary medical treatment for heavy menstrual bleeding.
5. Emergency Contraceptive Pills (ECPs)
Levonorgestrel (LNG 1.5 mg single dose / E-Pill): Must be taken within 72 hours of unprotected coitus. Prevents or delays ovulation. Ineffective once blastocyst implantation has occurred.
Ulipristal Acetate (30 mg single dose): Progesterone receptor modulator effective up to 120 hours (5 days).
Copper-T 380A: Inserted up to 5 days post-unprotected intercourse; most effective emergency contraceptive modality (>99% reduction in pregnancy risk).
- Permanent Contraceptive Methods (Sterilization)
- 1. Female Sterilization (Tubal Ligation)
Techniques:
Pomeroy Technique: Most widely performed abdominal method. A loop of the mid-ampullary portion of the fallopian tube is elevated, ligated at its base with absorbable suture (chromic catgut), and the top of the loop is resected.
Laparoscopic Occlusion: Application of Filshie clips or Falope rings (silastic bands) to the ampullary-isthmic junction.
Timing:
Puerperal / Postpartum Sterilization: Performed within 24–48 hours post-delivery via a small subumbilical minilaparotomy incision.
Interval Sterilization: Performed during the follicular phase of the menstrual cycle.
Failure Rate: ~0.5% (1 in 200). If pregnancy occurs post-ligation, ectopic pregnancy must be ruled out immediately.
2. Male Sterilization (No-Scalpel Vasectomy - NSV)
Technique: Performed under local anesthesia. The vas deferens is isolated using a specialized ring-pinning forceps through a single tiny puncture in the anterior scrotal skin (no incision/scalpel used). A 1 cm segment of the vas is excised, and the cut ends are ligated and cauterized.
Post-Procedure Protocol & Verification: Vasectomy does NOT result in immediate sterility due to viable spermatozoa stored in the distal vas deferens and seminal vesicles.
Patient must use alternative barrier contraception for 3 months or 20 ejaculations post-procedure.
Sterility is confirmed only when a Post-Vasectomy Semen Analysis (PVSA) performed at 3 months demonstrates complete azoospermia (or <100,000 non-motile sperm/mL).
Contraceptive Efficacy & Failure Rate Comparison
- Method Mechanism Typical Use Failure Rate Perfect Use Failure Rate Active Duration
- Subdermal Implant (Etonogestrel) Progestin-mediated LH suppression 0.05% 0.05% 3 years
- LNG-IUS (Mirena) Local endometrial suppression 0.2% 0.2% 5–8 years
- No-Scalpel Vasectomy Occlusion of vas deferens 0.15% 0.1% Permanent
- Female Tubal Ligation Occlusion of fallopian tubes 0.5% 0.5% Permanent
- Copper-T 380A Spermicidal copper inflammatory reaction 0.8% 0.6% 10 years
- DMPA Injectable (Antara) Ovulation suppression 4.0% 0.2% 3 months
- Centchroman (Chhaya) Non-steroidal SERM anti-implantation 1–2% 1.0% Dose-dependent
- COCPs (Mala-N) FSH/LH suppression + mucus thickening 7.0% 0.3% Daily
- Male Condom (Nirodh) Physical barrier 13.0% 2.0% Per coitus